

**VARNAVAS HADJIPANAYIS LTD (representing Novo Nordisk) 2018**

Date of publication: 28/6/2019

	Full Name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier <i>OPTIONAL</i>  <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL <i>OPTIONAL</i>	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
<b>INDIVIDUAL NAMED DISCLOSURE - one line per HCP</b> (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
HCPs	Dr. Stelios Vouniotis	Nicosia	Cyprus	20 Lefkotheou Avenue, 2054		N/A	N/A	173.60C	805 €	0 €	0 €	978.6C	
	Dr. Doros Polydorou	Nicosia	Cyprus	41 Andrea Avraamide Street, 2024		N/A	N/A	759.11C	5,801.07C	0 €	0 €	6,560.18C	
	Dr. Yiannakis Ioannou	Limassol	Cyprus	19 Nafpliou Street, 3025		N/A	N/A	186 €	860 €	0 €	0 €	1,046 €	
	<b>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</b>												
<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>						N/A	N/A	2,054.4C	6,661.64C	0 €	0 €	8,716.04	
<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>						N/A	N/A	8	8	0	0	Optional	
<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>						N/A	N/A	72.70%	72.70%	0%	0%	N/A	
<b>INDIVIDUAL NAMED DISCLOSURE - one line per HCO</b> (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)													
HCOs	Cyprus Society for the Study of Diabetes	Limassol	Cyprus	3 Pekinou Street, 3021				1,000 €				1,000 €	
	Cyprus Endocrine Society	Larnaka	Cyprus	41 Andrea Avraamide Street, 2024				3,000 €				3,000 €	
	<b>OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</b>												
	<b>Aggregate amount attributable to transfers of value to such Recipients - Art. 3.02</b>						0 €	0 €	0 €	0 €	0 €	0 €	Optional
<b>Number of Recipients in aggregate disclosure - Art. 3.02</b>						0	0	0	0	0	0	Optional	
<b>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art. 3.02</b>						%	%	%	%	%	%	N/A	
R & D	<b>AGGREGATE DISCLOSURE</b>												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 1											TOTAL AMOUNT	1,046 €